PT  - JOURNAL ARTICLE
AU  - Brigitte Hurtubise
AU  - Elliot M. Frohman
AU  - Steven Galetta
AU  - Laura J. Balcer
AU  - Teresa C. Frohman
AU  - Robert P. Lisak
AU  - Scott D. Newsome
AU  - Jennifer S. Graves
AU  - Scott S. Zamvil
AU  - Lilyana Amezcua
TI  - MOG Antibody–Associated Disease and Thymic Hyperplasia
AID  - 10.1212/NXI.0000000000200077
DP  - 2023 Mar 01
TA  - Neurology - Neuroimmunology Neuroinflammation
PG  - e200077
VI  - 10
IP  - 2
4099  - http://nn.neurology.org/content/10/2/e200077.short
4100  - http://nn.neurology.org/content/10/2/e200077.full
SO  - Neurol Neuroimmunol Neuroinflamm2023 Mar 01; 10
AB  - Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) is a recently described CNS inflammatory disorder that may manifest with optic neuritis, myelitis, seizures, and/or acute disseminated encephalomyelitis. While MOG-specific antibodies in patients with MOGAD are IgG1, a T-cell–dependent antibody isotype, immunologic mechanisms of this disease are not fully understood. Thymic hyperplasia can be associated with certain autoimmune diseases. In this report we describe a case of MOGAD associated with thymic hyperplasia in a young adult.Ab=antibody; AQP4=aquaporin 4 antibody; CRION=chronic relapsing inflammatory ON; CRP=C-reactive protein; ED=emergency department; ESR=erythrocyte sedimentation rate; FLAIR=fluid-attenuated inversion recovery; IgG=immunoglobulin G; IV-MP=IV methylprednisolone; MOG=myelin oligodendrocyte glycoprotein; MOGAD=MOG antibody–associated disease; NMOSD=neuromyelitis optica spectrum disorders; NMO=neuromyelitis optica; ON=optic neuritis; TLH=thymic lymphocytic hyperplasia